E-LIB Suche - Ergebnisse für: Wacheck, V

1

POSA354 Patient-Reported Outcomes in Futibatinib-Treated In..:

Bridgewater, JA ; Hollebecque, A ; Furuse, J...
Value in Health. 25 (2022) 1 - p. S218-S219 , 2022

Link: https://doi.org/10.1016/..

2

CO78 Matching-Adjusted Indirect Comparison of Futibatinib V..:

Paine, A ; Thom, H ; Wacheck, V...
Value in Health. 25 (2022) 12 - p. S33 , 2022

Link: https://doi.org/10.1016/..

3

Innovation in oncology clinical trial design:

Verweij, J. ; Hendriks, H.R. ; Zwierzina, H....
Cancer Treatment Reviews. 74 (2019) - p. 15-20 , 2019

Link: https://doi.org/10.1016/..

4

PRM160 - IMPACT OF POST-PROGRESSION OLARATUMAB (OLARA) MONO..:

Dyachkova, Y ; Lai, Y ; Peterson, PM..
Value in Health. 21 (2018) - p. S383-S384 , 2018

Link: https://doi.org/10.1016/..

5

Characterization of NVX‐207, a novel betulinic acid‐derived..:

Willmann, M. ; Wacheck, V. ; Buckley, J....
European Journal of Clinical Investigation. 39 (2009) 5 - p. 384-394 , 2009

Link: https://doi.org/10.1111/..

6

Differential role of circulating endothelial progenitor cel..:

Sieghart, W. ; Fellner, S. ; Reiberger, T....
Digestive and Liver Disease. 41 (2009) 12 - p. 902-906 , 2009

Link: https://doi.org/10.1016/..

7

Suppression of mTOR complex 2-dependent AKT phosphorylation..:

Werzowa, J. ; Cejka, D. ; Fuereder, T....
British Journal of Dermatology. 160 (2009) 5 - p. 955-964 , 2009

Link: https://doi.org/10.1111/..

8

SPC2996 – a potent, specific, long-lived and safe inhibitor..:

Hedtjärn, M. ; Høg, A. Mølhart ; Frieden, M....
European Journal of Cancer Supplements. 6 (2008) 9 - p. 109 , 2008

Link: https://doi.org/10.1016/..

9

P048 A CLINICAL TRIAL ON ABSORPTION AND N-ACETYLATION OF OR..:

Dilger, K. ; Trenk, D. ; Rössle, M....
Journal of Crohn's and Colitis Supplements. 1 (2007) 1 - p. 16 , 2007

Link: https://doi.org/10.1016/..

10

A clinical trial on absorption and N‐acetylation of oral an..:

Dilger, K. ; Trenk, D. ; Rössle, M....
European Journal of Clinical Investigation. 37 (2007) 7 - p. 558-565 , 2007

Link: https://doi.org/10.1111/..

11

Expression of the target receptor CD33 in CD34+/CD38−/CD123..:

Hauswirth, A.W. ; Florian, S. ; Printz, D....
European Journal of Clinical Investigation. 37 (2006) 1 - p. 73-82 , 2006

Link: https://doi.org/10.1111/..

12

69 POSTER Therapeutic effect of everolimus (RAD001) in comb..:

Cejka, D. ; Preusser, M. ; Sieghart, W....
European Journal of Cancer Supplements. 4 (2006) 12 - p. 25 , 2006

Link: https://doi.org/10.1016/..

13

583 POSTER mTORC1 inhibition with rapamycin leads to activa..:

Werzowa, J. ; Pratscher, B. ; Cejka, D...
European Journal of Cancer Supplements. 4 (2006) 12 - p. 176-177 , 2006

Link: https://doi.org/10.1016/..

14

Antisense molecules for targeted cancer therapy:

Wacheck, V. ; Zangemeister-Wittke, U.
Critical Reviews in Oncology/Hematology. 59 (2006) 1 - p. 65-73 , 2006

Link: https://doi.org/10.1016/..

15

278 mTOR Inhibition for patients with hepatocellular carcin..:

Sieghart, W. ; Fuereder, T. ; Schmid, K....
Journal of Hepatology. 44 (2006) - p. S109 , 2006

Link: https://doi.org/10.1016/..